Načítá se...
IMMU-02. TARGETING CD200 ACTIVATION RECEPTORS TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT: A NEW DIRECTION FOR CHECKPOINT IMMUNOTHERAPY
Glioblastoma multiforme is an incurable primary brain tumor. The standard of care consists of resection followed by radiation and chemotherapy is associated with a median overall survival of 14.6 months. To address this dismal outcome, aggressive interventions need to be pursued. Recently, the FDA a...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475077/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.113 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|